Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 7.5% – Still a Buy?

Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) were up 7.5% during mid-day trading on Friday . The company traded as high as $12.16 and last traded at $12.04. Approximately 317,530 shares were traded during mid-day trading, a decline of 74% from the average daily volume of 1,202,066 shares. The stock had previously closed at $11.20.

More Phathom Pharmaceuticals News

Here are the key news stories impacting Phathom Pharmaceuticals this week:

• Positive Sentiment: Q1 revenue beat consensus — Phathom reported $58.3M in revenue (above analyst estimates around $55.9M), showing top-line strength as VOQUEZNA® sales grow. Press Release / Slide Deck
• Positive Sentiment: Commercial visibility at DDW 2026 — Phathom announced it will highlight VOQUEZNA (vonoprazan) at the Digestive Disease Week meeting (May 2–5), which can support ongoing uptake and awareness among GI specialists. DDW Participation
• Neutral Sentiment: Earnings materials and call available — Management provided an earnings presentation and the full call transcript, useful for investors digging into product trends, channel fill, and cost dynamics. (See Seeking Alpha slides/transcript.) Earnings Presentation Earnings Transcript
• Negative Sentiment: Small EPS miss — GAAP/adjusted EPS loss of $0.18 missed consensus by $0.01, continuing an unprofitable profile (loss narrowed year-over-year but still negative). Q1 Results
• Negative Sentiment: FY2026 revenue guidance range implies mixed outlook — management guided revenue of $320M–$345M versus consensus near $331.9M; the range brackets the consensus but the lower bound is below street expectations, leaving some uncertainty on full-year trajectory. (EPS guidance detail was not provided in the entry.)

Analyst Ratings Changes

A number of equities research analysts recently issued reports on PHAT shares. Guggenheim upped their target price on Phathom Pharmaceuticals from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research note on Tuesday, April 21st. Stifel Nicolaus set a $28.00 target price on Phathom Pharmaceuticals in a research note on Thursday, February 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, January 14th. Finally, Barclays raised Phathom Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $16.00 to $18.00 in a research note on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Phathom Pharmaceuticals Stock Performance

The company has a fifty day simple moving average of $11.52 and a two-hundred day simple moving average of $13.43. The company has a market capitalization of $953.95 million, a price-to-earnings ratio of -5.67 and a beta of 0.57.

Phathom Pharmaceuticals (NASDAQ:PHAT) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The business had revenue of $57.58 million during the quarter, compared to analyst estimates of $57.44 million. As a group, analysts expect that Phathom Pharmaceuticals, Inc. will post -0.12 EPS for the current year.

Institutional Trading of Phathom Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in PHAT. AQR Capital Management LLC increased its holdings in shares of Phathom Pharmaceuticals by 508.2% during the 1st quarter. AQR Capital Management LLC now owns 107,399 shares of the company’s stock worth $673,000 after buying an additional 89,741 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Phathom Pharmaceuticals by 0.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 138,516 shares of the company’s stock worth $1,328,000 after buying an additional 1,123 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Phathom Pharmaceuticals by 13.8% during the 2nd quarter. Rhumbline Advisers now owns 64,557 shares of the company’s stock worth $619,000 after buying an additional 7,818 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Phathom Pharmaceuticals by 13.4% during the 2nd quarter. Invesco Ltd. now owns 4,140,072 shares of the company’s stock worth $39,703,000 after buying an additional 489,260 shares during the last quarter. Finally, Nebula Research & Development LLC increased its holdings in shares of Phathom Pharmaceuticals by 31.6% during the 2nd quarter. Nebula Research & Development LLC now owns 37,937 shares of the company’s stock worth $364,000 after buying an additional 9,116 shares during the last quarter. 99.01% of the stock is currently owned by institutional investors and hedge funds.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a clinical?stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium?competitive acid blocker (P-CAB) licensed for use in the United States.